EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery

Lung cancer is the leading cause of cancer-related deaths worldwide. New therapies targeting the epidermal growth factor receptor (EGFR) tyrosine kinase are promising and show high response rates in the subset of patients with activating mutations in EGFR. The frequency of these mutations is largely...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 6; no. 5; pp. 947 - 950
Main Authors Helland, Åslaug, Skaug, Hege Marian, Kleinberg, Lilach, Iversen, Marius Lund, Rud, Ane Kongsgaard, Fleischer, Thomas, Sagerup, Camilla, Solberg, Steinar, Jørgensen, Lars, Ariansen, Sarah, Brustugun, Odd Terje
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2011
International Association for the Study of Lung Cancer
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Lung cancer is the leading cause of cancer-related deaths worldwide. New therapies targeting the epidermal growth factor receptor (EGFR) tyrosine kinase are promising and show high response rates in the subset of patients with activating mutations in EGFR. The frequency of these mutations is largely unknown in unselected Caucasian patients. Mutation analysis of EGFR exons 18–21 was performed on 240 lung cancer samples using the TheraScreen EGFR mutation kit and denaturing high-performance liquid chromatography in addition to sequencing. In a cohort of 240 Norwegian lung cancer patients selected for surgery, we identified 18 tumors with EGFR-activating mutations (7.5%, 14 women and 4 men), of which 14 were adenocarcinomas, 2 squamous cell carcinomas, and 2 bronchoalveolar carcinomas. Five of the mutations were found in patients with more than 20 pack-years of smoking history. The frequency of EGFR mutations is lower in our cohort than among Asian lung cancer patients and present in both men and women and smokers and never-smokers. However, the frequency is significantly higher among women and never-smokers and among patients with adenocarcinomas.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1556-0864
1556-1380
DOI:10.1097/JTO.0b013e31820db209